Post- marketing erfaring viser, at bivirkninger, herunder hypoglykæmi, er rapporteret i sjældne tilfælde (> 1/ 10. 000 < 1/ 1. 000).
Based on post-marketing experience adverse drug reactions including hypoglycaemia have been reported rarely (> 1/ 10,000 < 1/ 1,000).